AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
184.45
+0.07 (0.04%)
At close: Nov 13, 2026, 4:00 PM EST
185.01
+0.56 (0.30%)
After-hours: Nov 13, 2026, 7:58 PM EST
AstraZeneca Revenue
AstraZeneca had revenue of $16.21B in the quarter ending September 30, 2026, with 6.70% growth. This brings the company's total for the last twelve months to $62.38B, up 7.32% year-over-year. In the year 2025, AstraZeneca had annual revenue of $58.74B with 8.63% growth.
Revenue (ttm)
$62.38B
Revenue Growth
+7.32%
P/S Ratio
4.60
Revenue / Employee
$655,983
Employees
95,100
Market Cap
286.76B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full AstraZeneca breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 58.74B | 4.67B | 8.63% |
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
| Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
| Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
| Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
| Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
| Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
| Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
| Dec 31, 2011 | 33.59B | 322.00M | 0.97% |
| Dec 31, 2010 | 33.27B | 465.00M | 1.42% |
| Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
| Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
| Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
| Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
| Dec 31, 2005 | 23.95B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 99.34B |
| Merck & Co. | 67.38B |
| AbbVie | 66.01B |
| Pfizer | 63.62B |
| Sanofi | 57.89B |
| Novartis AG | 57.36B |
| Novo Nordisk | 50.70B |
| Bristol-Myers Squibb Company | 50.03B |
AZN News
- 2 days ago - AZN : FDA Okays IMFINZI Combination Regimen For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - Nasdaq
- 2 days ago - AstraZeneca announces FDA approval of imfinzi/EV combination - TheFly
- 2 days ago - Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer - Business Wire
- 2 days ago - AstraZeneca’s Alexion receives FDA approval for Klygefa - TheFly
- 2 days ago - FDA approves AstraZeneca combo treatment for bladder cancer - TheFly
- 2 days ago - AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports - Reuters
- 2 days ago - AstraZeneca cuts 600 sales jobs in U.S., Bloomberg reports - TheFly
- 2 days ago - EU panel backs AstraZeneca hypertension drug baxdrostat - Reuters